



UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:
Donald R. Owen

Serial No.: 09/820,053

Filed: March 28, 2001

For: Short Bioactive Peptides

§ Group Art No.: Not assigned
§
§
§ Examiner: Not assigned
§
§ Att'y Docket No.: 068370.0104
§
§ Client Docket No.: HELX:027

TRANSMITTAL LETTER

Commissioner for Patents
Washington, D.C. 20231

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on April 23, 2001

Donald R. Owen
Signature

Applicant, Donald R. Owen, hereby submits the following document to be filed with the United States Patent and Trademark Office:

1. Information Disclosure Statement and PTO Form 1449 with 41 references;
2. Postcard.

Please date stamp and return the enclosed postcard evidencing receipt of the above mentioned document. We authorize the Commissioner to debit Deposit Account No. 02-0383 of Baker Botts L.L.P. for any underpayment of fees which may be due in association with this filing.

Respectfully submitted,



Christopher J. Buntel, Ph.D.
Reg. No. 44,573
Customer No. 23640
AGENT FOR ASSIGNEE,
HELIX BIOMEDIX, INC.

Baker Botts, L.L.P.
One Shell Plaza
910 Louisiana
Houston, TX 77002-4995
(713) 229-1992

April 23, 2001



In re patent application of: § Group Art No.: Not assigned
Donald R. Owen § § Examiner: Not assigned
Serial No.: 09/820,053 § § Att'y Docket No.: 068370.0104
Filed: March 28, 2001 § § Client Docket No.: HELX:027
For: SHORT BIOACTIVE PEPTIDES § §

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date below:	
April 23, 2001	 Signature

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the

HOU03:718293.1

filings of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to this document, the Commissioner is hereby authorized to deduct the fees from Baker Botts, L.L.P. Deposit Account 02-0383.

Respectfully submitted,



Christopher J. Buntel, Ph.D.
Reg. No. 44,573
Customer No. 23640
AGENT FOR ASSIGNEE,
HELIX BIOMEDIX, INC.

Baker Botts, L.L.P.
One Shell Plaza
910 Louisiana
Houston, TX 77002-4995
(713) 229-1992

April 23, 2001